Second-Chance CAR-T: new therapy targets lymphoma that outsmarted first treatment
NCT ID NCT04316624
Summary
This study tested the safety and effectiveness of a new CAR-T cell therapy called C-CAR066. It was for patients with an aggressive type of lymphoma (DLBCL) that had returned or not responded after they had already received a different CAR-T treatment. The goal was to see if this second, differently targeted CAR-T therapy could help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Institute of Hematology & Blood Diseases Hospital
Tianjin, 300020, China
Conditions
Explore the condition pages connected to this study.